Progenics Pharmaceuticals, Inc. Signs Commercial License Agreement with Selexis SA for Use of Proprietary Cell Line and SUREtechnology Platform
Geneva, Switzerland, 21 June 2016 – Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, announced today that Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) has entered into a commercial license agreement for the use of Selexis’ technology and proprietary CHO-K1 cell line.
Under the agreement, Progenics will have use of the Selexis CHO-M Cell Line™ and the SUREtechnology Platform™ for the development, manufacture, and commercialization of Progenics’ prostate specific membrane antigen (PSMA) antibody. Financial terms were not disclosed.
“Progenics is an important oncology company, seeking to improve the lives of prostate cancer patients and their families. We at Selexis look forward to seeing the progress of the Progenics team in applying our proprietary cell line and technology platform to develop products going forward,” said Yemi Onakunle, PhD, vice president, licensing and business development, Selexis SA. “Our SUREtechnology Platform can facilitate rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum. It’s rewarding for us to list Progenics as one of our active commercial partners.”
· Web www.selexis.com
· LinkedIn www.linkedin.com/company/selexis-sa
· Twitter www.twitter.com/SelexisSA
· Facebook www.facebook.com/SelexisSA
Contact details
-
- Sarah Wakefield
-
KBI Biopharma Company Inquiries
SVP, Corporate Communications - swakefield@kbibiopharma.com
Related topics
Related news
KBI Biopharma Appoints Jean-Baptiste Agnus as Chief Business Officer
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Jean-Baptiste (JB) Agnus as Chi...
KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise with Appointment of Chief Quality Officer
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Peter Carbone as the new Chief Quality...
KBI Biopharma, Inc. and Argonaut Manufacturing Services, Inc. Forge Strategic Alliance to Support Global Biopharmaceu...
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Argonaut Manufacturing Services, Inc. (Argonaut), a cGMP contract man...
KBI Biopharma, Inc. Expands Global Portfolio with Launch of SUREmAb™ for Faster Monoclonal Antibody Development and M...
KBI Biopharma, Inc. (KBI Biopharma), a JSR Life Sciences company, today announced the launch of SUREmAb™, an offering built on the robustness of KBI’s SUREtechnology Platform, that allows for optim...
KBI Biopharma Continues to Strengthen Leadership and Expertise With Key Executive Appointments
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced four recent executive appointments to continue its momentum and vision of becoming a next-generation CDMO.